ANGPTL3 and metabolic syndrome: Future research should investigate the feasibility of using ANGPTL3, ANGPTL4, and ANGPTL8 as biomarkers in DR and assess whether ANGPTL3-targeted therapies can improve disease progression in DR while managing dyslipidemia.